Medindia LOGIN REGISTER
Medindia
Advertisement

FDA Approves Celltrion to Manufacture ORENCIA(R) (abatacept)

Wednesday, December 19, 2007 General News
Advertisement
INCHEON, South Korea, Dec. 18 Celltrion, Inc., a leadingKorean biopharmaceutical company, announces that it has received approval fromthe U.S. Food and Drug Administration (FDA) to serve as a contractmanufacturer to produce ORENCIA(R) (abatacept), a novel biologic agent for thetreatment of rheumatoid arthritis, developed by Bristol-Myers Squibb Company(NYSE: BMY). The Supplemental Biological License Application (sBLA) wassubmitted by Bristol-Myers Squibb Company to meet expected long-term demandfor ORENCIA(R).
Advertisement

Celltrion is the largest biopharmaceutical manufacturing facility in theAsia-Pacific region, and the only Asian large-scale cell-culture contractmanufacturing facility which has successfully obtained approval from the U.S.FDA.
Advertisement

"We are pleased to continue our strategic business partnership withBristol-Myers Squibb. Achieving sBLA approval from the FDA to manufactureORENCIA(R) is an important milestone that reinforces our vision to become afully integrated global biotechnology company," said Jung-Jin Seo, Chairmanand Chief Executive Officer of Celltrion. "Celltrion is dedicated to workingwith our business partners to exceed their quality requirements whileproviding manufacturing value. It is our commitment to quality service thatwill attract other global biopharmaceutical companies to our manufacturingcapabilities."

About Celltrion, Inc.

Celltrion, established in 2002, is a contract manufacturing organizationwith a headquarters in Incheon, South Korea. Celltrion, an emerging leader inthe biopharmaceutical industry, is dedicated to providing high qualityservices to accelerate product development, while offering scalablemanufacturing capabilities for our clients and business partners. Celltrionis also investing in research and development of its own products, as well aslicensing from biopharmaceutical research companies throughout the world, inorder to develop into a fully integrated biotechnology company. Furtherinformation can be found on our website http://www.celltrion.com.Contact information: Jae Chung Vice President, Business Development Tel 415-290-9826

SOURCE Celltrion, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close